Myopia Progression and the Effect of 7-Methylxanthine
Launched by TRIER RESEARCH LABORATORIES · Dec 6, 2005
Trial Information
Current as of June 19, 2025
Unknown status
Keywords
ClinConnect Summary
Participants are given tablets of 7-methylxanthine 400 mg per day or placebo tablets for 12 months. Axial length, cycloplegic refraction and corneal curvature is measured, as well as weight, height, blood pressure and heart rate. The participants are interviewed about possible CNS, gastrointestinal, or cardiopulmonal side effects.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children in the age 8-13 years with myopia and an axial growth rate of 0.15 mm or more per year.
- • -
- Exclusion Criteria:
- • Severe general ailment (for example diabetes, epilepsy, psychiatric disease) Eye diseases (for example cataract, keratoconus, chronic iritis, glaucoma)
- • -
About Trier Research Laboratories
Trier Research Laboratories is a leading clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative study design and rigorous scientific methodologies. With a commitment to excellence, Trier Research Laboratories collaborates with healthcare professionals and research institutions to conduct high-quality clinical trials across various therapeutic areas. Their comprehensive approach encompasses all phases of clinical development, ensuring compliance with regulatory standards while prioritizing participant safety and data integrity. By fostering a culture of collaboration and transparency, Trier Research Laboratories aims to accelerate the translation of scientific discoveries into effective therapies for patients in need.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Klaus Trier, MD
Study Chair
Trier Research Laboratories
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials